147 related articles for article (PubMed ID: 3076125)
1. Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative.
Slater EE; MacDonald JS
Drugs; 1988; 36 Suppl 3():72-82. PubMed ID: 3076125
[TBL] [Abstract][Full Text] [Related]
2. Computer-aided, resistance gene-guided genome mining for proteasome and HMG-CoA reductase inhibitors.
Jenkinson CB; Podgorny AR; Zhong C; Oakley BR
J Ind Microbiol Biotechnol; 2023 Feb; 50(1):. PubMed ID: 38061800
[TBL] [Abstract][Full Text] [Related]
3. Statins stimulate arachidonic acid release and prostaglandin I2 production in rat liver cells.
Levine L
Lipids Health Dis; 2003 Mar; 2():1. PubMed ID: 12689340
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Statin Therapy on Inflammatory Biomarkers: A Systematic Review.
Proute MC; Kothur N; Georgiou P; Serhiyenia T; Shi W; Kerolos ME; Pradeep R; Akram A; Khan S
Cureus; 2021 Sep; 13(9):e18273. PubMed ID: 34722051
[TBL] [Abstract][Full Text] [Related]
5. Severe facial clefting in Insig-deficient mouse embryos caused by sterol accumulation and reversed by lovastatin.
Engelking LJ; Evers BM; Richardson JA; Goldstein JL; Brown MS; Liang G
J Clin Invest; 2006 Sep; 116(9):2356-65. PubMed ID: 16955138
[TBL] [Abstract][Full Text] [Related]
6. Impaired HMG-CoA Reductase Activity Caused by Genetic Variants or Statin Exposure: Impact on Human Adipose Tissue, β-Cells and Metabolome.
Sarsenbayeva A; Jui BN; Fanni G; Barbosa P; Ahmed F; Kristófi R; Cen J; Chowdhury A; Skrtic S; Bergsten P; Fall T; Eriksson JW; Pereira MJ
Metabolites; 2021 Aug; 11(9):. PubMed ID: 34564389
[TBL] [Abstract][Full Text] [Related]
7. Erratum to: The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia.
Br J Haematol; 2024 Jun; 204(6):2520. PubMed ID: 38671586
[No Abstract] [Full Text] [Related]
8. Choosing the right lipid-regulating agent. A guide to selection.
Farmer JA; Gotto AM
Drugs; 1996 Nov; 52(5):649-61. PubMed ID: 9118815
[TBL] [Abstract][Full Text] [Related]
9. Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease.
Haria M; McTavish D
Drugs; 1997 Feb; 53(2):299-336. PubMed ID: 9028747
[TBL] [Abstract][Full Text] [Related]
10. Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias.
Lea AP; McTavish D
Drugs; 1997 May; 53(5):828-47. PubMed ID: 9129869
[TBL] [Abstract][Full Text] [Related]
11. Extending therapy options in treating lipid disorders: a clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor.
Stein EA
Drugs; 1998; 56 Suppl 1():25-31; discussion 33. PubMed ID: 9740538
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
13. Development and pharmacology of fluvastatin.
Jokubaitis LA
Br J Clin Pract Suppl; 1996 Jan; 77A():11-5. PubMed ID: 8729584
[TBL] [Abstract][Full Text] [Related]
14. 3-Hydroxy-3-methylglutaryl--coenzyme A reductase inhibitors in the treatment of hypercholesterolemia.
Hoeg JM; Brewer HB
JAMA; 1987 Dec; 258(24):3532-6. PubMed ID: 3316727
[TBL] [Abstract][Full Text] [Related]
15. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes.
Masters BA; Palmoski MJ; Flint OP; Gregg RE; Wang-Iverson D; Durham SK
Toxicol Appl Pharmacol; 1995 Mar; 131(1):163-74. PubMed ID: 7878672
[TBL] [Abstract][Full Text] [Related]
16. Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia.
Plosker GL; McTavish D
Drugs; 1995 Aug; 50(2):334-63. PubMed ID: 8521762
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology of competitive inhibitors of HMG-CoA reductase.
Corsini A; Maggi FM; Catapano AL
Pharmacol Res; 1995 Jan; 31(1):9-27. PubMed ID: 7784310
[No Abstract] [Full Text] [Related]
18. High-throughput functional assay in cystic fibrosis patient-derived organoids allows drug repurposing.
Spelier S; de Poel E; Ithakisiou GN; Suen SWF; Hagemeijer MC; Muilwijk D; Vonk AM; Brunsveld JE; Kruisselbrink E; van der Ent CK; Beekman JM
ERJ Open Res; 2023 Jan; 9(1):. PubMed ID: 36726369
[TBL] [Abstract][Full Text] [Related]
19. Off-Target Effect of Lovastatin Disrupts Dietary Lipid Uptake and Dissemination through Pro-Drug Inhibition of the Mesenteric Lymphatic Smooth Muscle Cell Contractile Apparatus.
Stephens M; Roizes S; von der Weid PY
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769187
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
